Review of Experimental Compounds Demonstrating Anti-Toxoplasma Activity.
Toxoplasma gondii is a ubiquitous apicomplexan parasite capable of infecting humans and other animals. Current treatment options for T. gondii infection are limited and most have drawbacks, including high toxicity and low tolerability. Additionally, no FDA-approved treatments are available for pregnant women, a high-risk population due to transplacental infection. Therefore, the development of novel treatment options is needed. To aid this effort, this review highlights experimental compounds that, at a minimum, demonstrate inhibition of in vitro growth of T. gondii When available, host cell toxicity and in vivo data are also discussed. The purpose of this review is to facilitate additional development of anti-Toxoplasma compounds and potentially to extend our knowledge of the parasite.
Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA.
Madalyn M
MM
McFarland
Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA.
Sydney J
SJ
Zach
College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Xiaofang
X
Wang
Division of Infectious Diseases, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Lakshmi-Prasad
LP
Potluri
Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA.
Andrew J
AJ
Neville
College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jonathan L
JL
Vennerstrom
Department of Biology, University of Nebraska at Omaha, Omaha, Nebraska, USA pdavis@unomaha.edu.
Paul H
0000-0002-0526-3841
PH
Davis
D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D058492:Drug Repositioning; D006790:Host-Parasite Interactions / Q000187:drug effects; D006801:Humans; D014122:Toxoplasma / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity
D000981:Antiprotozoal Agents